Merck KGaA MKKGY
32.83 USD -0.25 (-0.76%)
Regular-session close
32.78 Day range 33.12
23.73 52-week range 34.19
- YTD
- +14.47%
- 1 year
- +26.17%
- Market cap
- 71.37B
- EPS (ttm)
- 1.03
- P/E ratio
- 31.87
- YTD return
- +14.47%
- 1-year return
- +26.17%
- Volume
- 18.03K
- Avg volume
- 97.80K
- Open
- 33.01
- Previous close
- 33.08
- Day's range
- 32.78 – 33.12
- 52-week range
- 23.73 – 34.19
5D +0.41 (+1.26%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | 0.46 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 0.47 | 0.26 | -0.21 | -44.68% |
| May 13, 2026 | Mar 31, 2026 | 0.45 | 0.59 | +0.14 | +31.11% |
| Mar 5, 2026 | Dec 31, 2025 | 0.47 | 0.28 | -0.19 | -40.43% |
| Nov 13, 2025 | Sep 30, 2025 | 0.54 | 0.81 | +0.27 | +50.00% |
| Aug 7, 2025 | Jun 30, 2025 | 0.51 | 0.57 | +0.06 | +11.76% |
News
Merck KGaA (MKKGY) Q3 2026 Earnings Call Transcript
Why Is Silence Therapeutics Stock Skyrocketing Monday?
Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
Merck KGaA (OTCMKTS:MKKGY) versus MediciNova (NASDAQ:MNOV) Head-To-Head Contrast
Merck KGaA (OTCMKTS:MKKGY) Shares Shorted: Short Interest Up 95.4% in September
Merck KGaA (OTCMKTS:MKKGY) Receives Consensus Rating of “Hold” from Brokerages
Merck KGaA (MKKGY) Q2 2026 Earnings Call Transcript
Merck KGaA (MKKGY) Misses Q2 Earnings Estimates
Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development
Merck KGaA (MKKGY) Moves to Strong Buy: Rationale Behind the Upgrade
Your note
Sign in to keep a note on MKKGY — it syncs with the Stock Master app.
